|252.37||+2.23||+0.89%||Vol 354.97K||1Y Perf -8.43%|
|Feb 2nd, 2023 11:44 DELAYED|
|-0.34 -0.14%||- -|
|Target Price||267.50||Analyst Rating||Moderate Buy 1.59|
|Potential %||5.39||Finscreener Ranking||★★★+ 51.03|
|Insiders Trans % 3/6/12 mo.||100/-82/-88||Value Ranking||★★★★ 54.91|
|Insiders Value % 3/6/12 mo.||100/-99/-99||Growth Ranking||★★★★ 59.35|
|Insiders Shares Cnt. % 3/6/12 mo.||100/-99/-99||Income Ranking||★+ 36.72|
|Price Range Ratio 52W %||57.90||Earnings Rating||Sell|
|Market Cap||22.36B||Earnings Date||16th Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||16th Feb 2023|
|Estimated EPS Next Report||4.06|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||500.83K|
|Avg. Monthly Volume||545.25K|
|Avg. Quarterly Volume||663.43K|
Laboratory Corporation of America Holdings (NYSE: LH) stock closed at 250.14 per share at the end of the most recent trading day (a -0.79% change compared to the prior day closing price) with a volume of 732.78K shares and market capitalization of 22.36B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 72400 people. Laboratory Corporation of America Holdings CEO is Adam H. Schechter.
The one-year performance of Laboratory Corporation of America Holdings stock is -8.43%, while year-to-date (YTD) performance is 6.23%. LH stock has a five-year performance of 47.44%. Its 52-week range is between 200.32 and 290.2, which gives LH stock a 52-week price range ratio of 57.90%
Laboratory Corporation of America Holdings currently has a PE ratio of 13.00, a price-to-book (PB) ratio of 2.13, a price-to-sale (PS) ratio of 1.93, a price to cashflow ratio of 11.30, a PEG ratio of 2.32, a ROA of 9.36%, a ROC of 11.40% and a ROE of 18.48%. The company’s profit margin is 10.75%, its EBITDA margin is 20.10%, and its revenue ttm is $11.20 Billion , which makes it $126.44 revenue per share.
Of the last four earnings reports from Laboratory Corporation of America Holdings, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.06 for the next earnings report. Laboratory Corporation of America Holdings’s next earnings report date is 16th Feb 2023.
The consensus rating of Wall Street analysts for Laboratory Corporation of America Holdings is Moderate Buy (1.59), with a target price of $267.5, which is +5.39% compared to the current price. The earnings rating for Laboratory Corporation of America Holdings stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Laboratory Corporation of America Holdings has a dividend yield of 1.18% with a dividend per share of $2.88 and a payout ratio of -%.
Laboratory Corporation of America Holdings has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.31, ATR14 : 4.50, CCI20 : -15.24, Chaikin Money Flow : 0.32, MACD : 3.94, Money Flow Index : 37.18, ROC : -0.62, RSI : 54.99, STOCH (14,3) : 35.16, STOCH RSI : 0.00, UO : 56.73, Williams %R : -64.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Laboratory Corporation of America Holdings in the last 12-months were: Adam H. Schechter (Option Excercise at a value of $0), Amy B. Summy (Option Excercise at a value of $0), Amy B. Summy (Sold 249 shares of value $65 290 ), Brian J. Caveney (Buy at a value of $40 852), Brian J. Caveney (Option Excercise at a value of $0), D. Gary Gilliland (Option Excercise at a value of $0), Garheng Kong (Option Excercise at a value of $0), Glenn A. Eisenberg (Option Excercise at a value of $4 722 543), Glenn A. Eisenberg (Sold 57 100 shares of value $13 417 023 ), Jean-Luc Belingard (Option Excercise at a value of $0), Jeffrey A. Davis (Option Excercise at a value of $0), Judith C. Seltz (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $0), Kerrii B. Anderson (Option Excercise at a value of $0), Lance V. Berberian (Option Excercise at a value of $0), Mark Schroeder (Option Excercise at a value of $0), Mark Schroeder (Sold 4 044 shares of value $1 069 592 ), Paul Kirchgraber (Option Excercise at a value of $0), Peter J. Wilkinson (Option Excercise at a value of $112 435), Peter J. Wilkinson (Sold 2 576 shares of value $665 635 ), Peter M. Neupert (Option Excercise at a value of $0), Richelle P. Parham (Option Excercise at a value of $0), Robert Sanders Williams (Option Excercise at a value of $0), Robert Sanders Williams (Sold 572 shares of value $156 145 ), Sandra D. van der Vaart (Option Excercise at a value of $0), Sandra D. van der Vaart (Sold 3 046 shares of value $842 576 )
Mon, 31 Oct 2022 04:25 GMT Laboratory (LH) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Wed, 03 Aug 2022 02:29 GMT Laboratory (LH) Receives a Buy from Robert W. Baird- TipRanks. All rights reserved.
Mon, 01 Aug 2022 12:36 GMT Analysts Offer Insights on Healthcare Companies: Laboratory (LH), Teleflex (TFX) and Amedisys (AMED)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.